(MedPage Today) — The FDA granted a first-ever approval for a first-line therapy for anal cancer to the PD-1 inhibitor retifanlimab (Zynyz), the agency announced Thursday.
The approval stipulates use in combination with carboplatin and paclitaxel…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/115607
Author :
Publish date : 2025-05-15 21:30:00
Copyright for syndicated content belongs to the linked Source.
